News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk (NVO) Release: The World's Largest Insulin Supplier To Invest More Than $100 Million In Clayton Facility Expansion


10/19/2005 5:11:59 PM

CLAYTON, N.C., Oct. 28 /PRNewswire-FirstCall/ -- Governor Mike Easley and Novo Nordisk, a world leader in diabetes care, today announced plans for $100 million expansion of Novo Nordisk's insulin manufacturing facility in Clayton, North Carolina. The company plans to break ground on the new 181,000 square foot addition within the next few months.

The first phase of the facility expansion, scheduled for completion in 2006, will allow Novo Nordisk to more than double its insulin filling capabilities. The second phase of the expansion will include two new assembly and packaging lines to accommodate Novo Nordisk's insulin delivery device, FlexPen(R), as well as administration and storage space, with expected completion in 2007.

"Plans for the expansion demonstrate Novo Nordisk's commitment to serving the insulin needs of people who are living with diabetes throughout the US," said John R. Pratt, general manager, Novo Nordisk Pharmaceutical Industries, Inc. "Novo Nordisk is proud to be expanding its facility in Clayton and helping to create additional employment opportunities for the region."

Currently, the Clayton manufacturing facility handles the formulation, filling and packaging of Novo Nordisk's genetically engineered insulin preparations. The site is a high-volume, high-speed integrated facility that supplies the needs of the U.S. and other worldwide markets. Recently completed was a $12 million two-story addition, which expanded the world-class facilities quality inspection, cold storage capabilities and quality control laboratories, as well as additional administrative and employee areas.

Under Governor Easley's leadership, North Carolina's top ranked business climate prospers. In addition to Novo Nordisk's plans for expansion, General Electric, General Dynamics, and Merck & Company have chosen to expand their presence in North Carolina in the past year. Novo Nordisk's new expansion will provide 187 new jobs in the region for a total of 561 when fully operational.

"This announcement builds on our already thriving pharmaceutical industry here in North Carolina," said Easley. "One of the main reasons Novo Nordisk is expanding here is because of the training their employees will receive through the community college system. This is further proof that our investments in education, infrastructure and workforce development are paying off. To have a world leader in diabetes care expand here in Clayton and create 187 skilled jobs is a real win for our state."

Novo Nordisk owns an additional 210 acres for a total of 264 acres adjacent to the existing facility allowing opportunity for future development. In December 2003, Novo Nordisk donated eight acres to the Johnston County Industrial Development Corporation (JCIDC), a non-profit corporation, which identified Johnston Community College as a site for a 30,000 square foot training center. JCIDC entered into a management agreement with Johnston Community College to staff and run curriculum as well as continuing education courses from this facility. Groundbreaking for this facility was held in August 2004. Construction is expected to be completed in August 2005.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy and hormone therapy for women. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 19,600 full-time employees in 69 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com, or in the US, http://www.novonordisk-us.com/.

Novo Nordisk

CONTACT: Media, Susan Jackson, +1-609-919-7776, or Investors, ChristianKanstrup, +1-609-919-7937, both for Novo Nordisk


Read at BioSpace.com


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES